Dry Eye Treatment Devices Market Analysis

Dry Eye Treatment Devices Market Analysis

Based on technology, the dry eye treatment devices market is segmented as broadband light (BBL), intense pulsed light (IPL), meibomian gland expression (MGX) and combination (MGX+IPL). The meibomian gland expression (MGX) dominated the market accounting over 41% market share in 2022. Meibomian gland expression (MGX) is a technology used to address meibomian gland dysfunction (MGD), which is a common underlying cause of dry eye disease. For instance, according to the Dry Eye Directory, in 2020, around 1 billion people globally were suffering from meibomian gland dysfunction accounting around 86% of the total population suffering from dry eye disease. Meibomian glands are responsible for producing the oily layer of the tear film, which helps prevent evaporation of tears and maintain tear stability. Dysfunction or blockage of these glands leads to decreased tear quality. Meibomian gland expression helps to unclog the blocked glands and restore the flow of healthy lipids, improving tear quality and reducing tear evaporation.
 

MGX promotes more stable tears, reducing dryness, irritation, and fluctuations in vision associated with dry eye disease. Regular and proactive use of Meibomian gland expression can help prevent the progression of meibomian gland dysfunction and associated dry eye symptoms. By maintaining the health and function of the meibomian glands, MGX can help prevent future blockages and minimize the risk of developing severe dry eye disease. Therefore, owing to several benefits offered by meibomian gland expression (MGX), the market is estimated to witness a significant growth in the coming years.
 

Based on end-use, the dry eye treatment devices market is segmented as hospitals, ophthalmic clinics and others. The hospitals segment held a dominant market share and accounted for around USD 124 million in 2022. Hospitals, have a range of diagnostic equipment’s and tools to caters to a wide range of patients suffering from dry eye diseases and other related co-morbidities. Hospitals often have dedicated ophthalmology diagnostic departments where patients can access specialized care for dry eye disease. These facilities are equipped with advanced diagnostic tools and treatment options, including dry eye treatment devices, to provide comprehensive management for patients with more severe or complex cases. Hospitals have expert ophthalmologists and eye care specialists that can recommend and administer appropriate dry eye treatment devices as part of a comprehensive treatment plan, ensuring optimal patient care.
 

Hospitals offer a multidisciplinary approach to patient care, allowing for collaboration between various healthcare professionals. This integration can be particularly beneficial for individuals with underlying systemic conditions or comorbidities that contribute to dry eye disease. The availability of dry eye treatment devices in hospitals enables coordinated care and the integration of dry eye management with other medical treatments if necessary. Hospitals are integrated with advance state-of-the-art medical equipment and technologies, including dry eye treatment devices such as intense pulsed light (IPL), meibomian gland expression (MGX), or combination therapies to provide patients with optimal treatment options. The availability of advanced diagnostic tools, expertise, and multidisciplinary collaboration in hospitals contribute to improved patient outcomes and drive the demand for dry eye treatment devices in these settings.
 

North America region held a dominant share in the global dry eye treatment devices market and was valued at USD 95 million in 2022. This high market share is ascribed to a variety of factors, including the presence of significant industry players, an increase in the number of patients suffering from dry eye disease diseases, an expanding elderly population, among others. Factors such as aging demographics, extensive use of digital devices, and environmental conditions contribute to the high prevalence of dry eye in the region. For instance, according to the American Academy of Ophthalmology data, in 2022, around 20 million Americans were estimated to suffer from dry eye disease. As a result, the region is witnessing a growing demand for effective treatment options, including dry eye treatment devices. The availability advanced technologies such as intense pulsed light (IPL), meibomian gland expression (MGX), and combination therapies drives the product demand in the region.
 

North America has a robust healthcare system with well-established ophthalmology clinics and eye care centers. These facilities offer specialized care for dry eye disease and have access to a wide range of dry eye treatment devices. The availability of insurance coverage for dry eye treatment devices makes them more accessible and affordable for patients, leading to increased demand. The ongoing efforts in research and clinical trials foster innovation and advancements in treatment options, driving the market demand in North America. Therefore, high prevalence of dry eye disease, technological advancements, specialized healthcare infrastructure, increased awareness, insurance coverage, and active R&D activities contribute to the increasing demand for dry eye treatment devices in North America.